Plunkett Research Online: Eiger BioPharmaceuticals

EIGER BIOPHARMACEUTICALS (EIGR:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Eiger BioPharmaceuticals Inc is a late-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir,.....



Eiger BioPharmaceuticals
Ticker: EIGR
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 650 272-6138
Fax: 650 618-1621
Address: 2155 Park Boulevard
Palo Alto, CA 94306 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Vaccines, Skin Replacement Products and Biologicals Manufacturing
ContactsDescription

David CoryCEO/Director/President
Sriram RyaliCFO/Chief Accounting Officer
See More
Eiger BioPharmaceuticals Inc is a late-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir,.....See More See More

Auditor: KPMG LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201920182017201620152014
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: